Table 1 Table of evidence with main characteristics of the included studies
Reference | Design and registration details; founding | Country | Year of baseline data collection | N and clinical characteristics | Setting | Type of diabetes-related technology | Type of conventional treatment comparator | Inequality assessed from baseline characteristics | Outcomes | Length of follow-up |
|---|---|---|---|---|---|---|---|---|---|---|
Authors, year of publication, name of the study | Study design/registration number/founding | Country or region | Year | Number of patients assigned and that received each treatment (CSII:MDI); Sex (M:F); Age; Baseline characteristics of participants (including duration of the disease, baseline HbA1c [mean % (SD)] and HRQoL assessment tool); Other definition or comment | Community/clinical based research | Continuous subcutaneous insulin infusion (CSII), including the use of adjunctive glucose monitors: model of devices and insulin | Multiple daily injections (MDI): injections and insulins | A. Place of residence B. Race, ethnicity, culture and language C. Occupation D. Sex E. Religion F. Education G. Socioeconomic status H. Social capital | 1. HbA1c at the end of the study: CSII versus MDI [mean % (SD)], sig 2. Total number of hypoglycemic episodes: CSII versus MDI, sig 3. Number of patients with a frequency of ≥ 1 Ketoacidosis episode: CSII versus MDI, sig 4. Glycemic variability: % of time in range, hypo and/or hyperglycemia: CSII versus MDI, sig 5. HRQoL score (±SD) at the end of the study: CSII vs. MDI, sig | Duration of follow |